The Society for Immunotherapy of Cancer (SITC) hosted "Session 100: Lessons and Challenges from the Immunotherapy of Hematologic Malignancies: Informing the Next Generation of Cancer Immunotherapies" during the SITC 2019 Annual Meeting on November 7, 2019. This session was organized in collaboration with the American Society of Hematology (ASH). Available here are the presentation slides and video from the session.
34th Annual Meeting Organizers
Session Co-Chairs
Session Summary
In the past decade, the field of cellular therapy has emerged as a powerful treatment modality for advanced cancers refractory to conventional therapy. Genetic engineering of immune cells has evolved from a promising concept to a practical solution for the treatment of a number of previously refractory types of cancer. These exciting new therapies mark a paradigm shift in the treatment of certain hematologic malignancies, and are expected to cause a ripple effect in the field of cellular therapy and gene editing to target other cancers.
As hematologic malignancies have been on the frontline of developing novel cell-based immunotherapies with amongst the best response rates, this workshop focused on lessons learned from these trials and how they can inform the design of next-generation clinical studies. Presentations by leaders in the field provided an opportunity for attendees to gain a deeper understanding of the predictors and mechanisms of tumor escape, the contribution of the tumor microenvironment, and how this knowledge can be used for the development of novel immune therapeutic agents for the treatment of all types of cancer.
To view the entire program schedule (including presenter permission to post) please click here.
Meeting: SITC 34th Annual Meeting; Session 100: Lessons and Challenges from the Immunotherapy of Hematologic Malignancies: Informing the Next Generation of Cancer Immunotherapies; Presenter: Terry Fry, MD – University of Colorado School of Medicine, Children's Hospital Colorado; Date: November 7, 201900:26:47
Meeting: SITC 34th Annual Meeting; Session 100: Lessons and Challenges from the Immunotherapy of Hematologic Malignancies: Informing the Next Generation of Cancer Immunotherapies; Presenter: Zachary Walsh, BA – Children's Hospital Colorado; Date: November 7, 201900:11:30
Meeting: SITC 34th Annual Meeting; Session 100: Lessons and Challenges from the Immunotherapy of Hematologic Malignancies: Informing the Next Generation of Cancer Immunotherapies; Presenter: El-ad David Amir, PhD – Astrolabe Diagnostics, Inc.; Date: November 7, 201900:11:24
Meeting: SITC 34th Annual Meeting; Session 100: Lessons and Challenges from the Immunotherapy of Hematologic Malignancies: Informing the Next Generation of Cancer Immunotherapies; Presenter: Sergio Rutella, MD, PhD, FRCPath – Nottingham Trent University; Date: November 7, 201900:11:55
Meeting: SITC 34th Annual Meeting; Session 100: Lessons and Challenges from the Immunotherapy of Hematologic Malignancies: Informing the Next Generation of Cancer Immunotherapies; Presenter: Stephen Ansell, MD, PhD – Mayo Clinic; Date: November 7, 201900:22:57
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us